DiaGen AI
DiaGen AI Partners With Nasdaq:MEDS to Discover Novel Cancer Targets and Develop Anti-Cancer Peptide Pipeline
DiaGen AI, Inc. announced a partnership with Nasdaq:MEDS focused on discovering novel cancer targets and developing an anti-cancer peptide pipeline, according to the company. As part of the arrangement, DiaGen earned a 630,000 share equity stake in Nasdaq:MEDS, equivalent to 9.9% of the company, valued